• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Podcast: This Week in Managed Care—Responding to CMS and Other Health News

News
Podcast

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care news included comments to several proposals from CMS; Medicare advocates say voters will be motivated by healthcare cost concerns during the midterm elections; research showed diabetes drug dapagliflozin, an SGLT2 inhibitor, reduces risks of major cardiovascular events.

Listen above or through one of these podcast services:

iTunes: http://apple.co/2eYWTss

TuneIn: http://bit.ly/2gv7iwj

Stitcher: http://bit.ly/2gCqtFg

Read more about the stories in this podcast:

Hospital Groups, Others Raise Concerns Over CMS Payment Proposal

Senate Votes 98-2 to Ban Pharmacist Gag Clauses

What We're Reading: Safety-Net Readmissions; Gag Clause Bill to Trump; CREATES Impact on Drug Spend

Medicare Advocates Call for Keeping Program as It Is, Cite Voter Concerns About Costs

Diabetes Drug Farxiga Cuts Heart Risks in Topline Results

CVD-REAL Results in More Diverse Countries Link SGLT2s to Lower Risk of Death, Heart Attack, Stroke

Related Videos
Philip Mease, MD
Most employees are unprepared to shop for coverage on their own, underscoring the need for stronger decision tools and consumer protections.
Experts warn that ICHRAs could either stabilize or destabilize the individual market, depending on which workers employers shift into these plans.
Dr Marco del Riccio
Dr Marco del Riccio
Eleanor Perfetto, PhD
Tom Kim, chief medical officer, Sound Long-Term Care Management
Ciara Zachary, PhD, MPH
Related Content
© 2026 MJH Life Sciences
AJMC®
All rights reserved.